Clinical trial
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076
Study timeline
Study start (actual)2022-11-07Date precision: day
Registry last updated2025-05-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Alzheimer Diseaseunresolved
Interventions
SimufilamDRUG
Sponsors & collaborators
Cassava Sciences, Inc.lead sponsor
Mapped research locations
MiamiFlorida, United States4DallasTexas, United States2TorontoOntario, Canada2TampaFlorida, United States2PortlandOregon, United States2PhoenixArizona, United States2AlbanyNew York, United States2BrooklynNew York, United States2MelbourneVictoria, Australia2SherbrookeQuebec, Canada2Staten IslandNew York, United States2New YorkNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05575076 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.